Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
- Conditions
- Hypertension, Pulmonary
- Interventions
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT01824290
- Locations
- 🇧🇷
Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
🇵🇱Uniwersytecki Szpital Dzieciecy w Krakowie-Prokocimiu, Krakow, Poland
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2013-04-01
- Last Posted Date
- 2013-10-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01821703
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zuidlaren, Netherlands
A Study of LY2605541 in Healthy Participants and in the Elderly
- Conditions
- Healthy Volunteers
- Interventions
- Drug: LY2605541
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 52
- Registration Number
- NCT01818245
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy
- Conditions
- Hypogonadism
- Interventions
- Drug: Placebo SolutionDrug: Testosterone Solution
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2015-12-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 715
- Registration Number
- NCT01816295
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barnsley, United Kingdom
Study of Food on Evacetrapib (LY2484595) in Healthy Participants
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT01810432
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT01808651
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 513
- Registration Number
- NCT01808612
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
- Conditions
- Alzheimer DiseaseHealthy Volunteers
- Interventions
- Drug: LY2886721Drug: Placebo
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT01807026
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
- First Posted Date
- 2013-02-18
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 341
- Registration Number
- NCT01794000
- Locations
- 🇺🇸
Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Oakland, Oakland, California, United States
🇺🇸Stanford Univ Medical Center, Palo Alto, California, United States
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 212
- Registration Number
- NCT01792284
- Locations
- 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayamon, Puerto Rico